Special talk this afternoon- The inaugural Felix Feng Visiting Professorship. Dr. Paul Nguyen did phenomenal job highlighting the impact Felix had on so many of us.
NEW: A novel tool predicts long-term risk of dying from #ProstateCancer, helping doctors interpret PSA results more accurately. Tested on over 200K men, it could help doctors tailor screening and treatment to individual risk and life expectancy. Read now: https://t.co/OwVtJzueIS @stensy@wandering_gu@UMichUrology #Cancer #CancerScreening
Enhance your expertise in public health with our Summer Session in Epidemiology. Online from July 7-25, you'll gain skills in design and analysis of clinical trials from Dr. Matthew Schipper @StatMatt9@umichsph
Congratulations to Matt Schipper (@StatMatt9) for winning the @UMich Research Faculty Mentor Award. Matt has a tremendous record of supporting and training dozens of students, staff, trainees, and faculty, so this is very well-deserved! @UMichRadOnc@UMRogelCancer@MichRadOncRes
@DrSpratticus@SeanMcGuireMD@JoeBiden Yes plenty of events to train model with 8 predictors. More important was external validation on over 8000 men with over 2000 events.
A study from the @VAAnnArbor provides more data on the impact of lung cancer screening, this time evaluating the survival of a cohort of >2,000 screen-detected lung cancers. https://t.co/hOmkYgYweg
It is with profound sadness that we mourn the passing of Felix Feng—an incredible father, husband, UCSF leader, pioneering scientist, entrepreneur, mentor, and cherished friend. Felix’s enduring kindness, brilliant mind, generous spirit, and transformative work in prostate cancer research have touched and saved countless lives. His legacy of compassion, innovation, and excellence will continue to inspire us all. My deepest condolences to Mary, Eric, & Emily during this heartbreaking time. May the One who brings Peace bring Peace to All.💔
Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study Out on Lancet Oncology
This retrospective cohort study aimed to evaluate the effectiveness and safety of immune checkpoint inhibitors (ICIs) in Black patients, who were underrepresented in clinical trials leading to ICIs’ approval. Using data from the U.S. Veterans Health Administration, the study included 26,398 patients, of whom 18.7% were Black and 81.3% were White. Results showed that Black patients had a longer time to treatment discontinuation, similar time to next treatment, and slightly improved overall survival compared to White patients. Additionally, Black patients experienced significantly fewer immune-related adverse events, including lower risks of colitis and thyroid issues. These findings suggest that Black patients may have a more favorable therapeutic ratio for ICI treatment, though further investigation is needed to assess the generalizability of these results.
@StatMatt9@garthstrohbehn@DariaBrinzevich@KamyaSankar
https://t.co/FQhj7vg9k0